Company intelligence / Profile preview

Okogen

Delaware, United Statesokogen.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 2

Overview

Okogen is conducting clinical trials for its lead product as a treatment for all forms of acute infectious conjunctivitis. The company initiated a Phase 2 clinical trial for OKG-0301 to assess safety and efficacy, with top line results expected in early 2020. More recently, they submitted a regulatory application to CDSCO in India for a Phase IIb clinical trial called The Emerald Study[5].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (antiviral, antibacterial, ocular decongestant)
Industry: Biotech

Drug pipeline

3 assets

OKG-0502

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Okogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Okogen.

Explore the full profile